SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,375,215 | -12.3% | 303,780 | -4.4% | 0.01% | -14.3% |
| Q2 2023 | $9,546,936 | -21.2% | 317,596 | -5.0% | 0.01% | -22.2% |
| Q1 2023 | $12,116,435 | +0.0% | 334,431 | -1.5% | 0.01% | 0.0% |
| Q4 2022 | $12,114,815 | +4.4% | 339,636 | -0.9% | 0.01% | 0.0% |
| Q3 2022 | $11,606,000 | +9.5% | 342,860 | -6.4% | 0.01% | +12.5% |
| Q2 2022 | $10,596,000 | -17.0% | 366,391 | -7.2% | 0.01% | 0.0% |
| Q1 2022 | $12,760,000 | +5.1% | 394,796 | -5.2% | 0.01% | +14.3% |
| Q4 2021 | $12,138,000 | +0.2% | 416,254 | -8.4% | 0.01% | -12.5% |
| Q3 2021 | $12,118,000 | -13.2% | 454,356 | +0.2% | 0.01% | -11.1% |
| Q2 2021 | $13,967,000 | +24.0% | 453,613 | +5.4% | 0.01% | +12.5% |
| Q1 2021 | $11,267,000 | +5.6% | 430,381 | +1.5% | 0.01% | 0.0% |
| Q4 2020 | $10,667,000 | +35.1% | 423,982 | +11.9% | 0.01% | +14.3% |
| Q3 2020 | $7,894,000 | -15.7% | 378,791 | -4.0% | 0.01% | -12.5% |
| Q2 2020 | $9,369,000 | +30.7% | 394,503 | -1.0% | 0.01% | 0.0% |
| Q1 2020 | $7,170,000 | -27.4% | 398,561 | -4.2% | 0.01% | 0.0% |
| Q4 2019 | $9,871,000 | -20.1% | 416,158 | -7.4% | 0.01% | -27.3% |
| Q3 2019 | $12,356,000 | -16.1% | 449,647 | +1.0% | 0.01% | -15.4% |
| Q2 2019 | $14,735,000 | -9.0% | 445,300 | -3.7% | 0.01% | -13.3% |
| Q1 2019 | $16,198,000 | +4.9% | 462,280 | -0.5% | 0.02% | -6.2% |
| Q4 2018 | $15,437,000 | -32.3% | 464,681 | +2.7% | 0.02% | -20.0% |
| Q3 2018 | $22,788,000 | -11.9% | 452,597 | +4.8% | 0.02% | -16.7% |
| Q2 2018 | $25,859,000 | +33.5% | 432,067 | +2.1% | 0.02% | +26.3% |
| Q1 2018 | $19,376,000 | +18.6% | 423,062 | +3.2% | 0.02% | +26.7% |
| Q4 2017 | $16,331,000 | +0.4% | 409,824 | +0.7% | 0.02% | -6.2% |
| Q3 2017 | $16,271,000 | -7.6% | 406,775 | -0.5% | 0.02% | -11.1% |
| Q2 2017 | $17,614,000 | +37.5% | 408,678 | -0.1% | 0.02% | +20.0% |
| Q1 2017 | $12,809,000 | +29.6% | 409,242 | +4.6% | 0.02% | +15.4% |
| Q4 2016 | $9,882,000 | +6.9% | 391,378 | +4.7% | 0.01% | +8.3% |
| Q3 2016 | $9,248,000 | +85.4% | 373,963 | +52.7% | 0.01% | +71.4% |
| Q2 2016 | $4,988,000 | +38.6% | 244,861 | +3.8% | 0.01% | +40.0% |
| Q1 2016 | $3,598,000 | +18.0% | 235,958 | +4.0% | 0.01% | 0.0% |
| Q4 2015 | $3,049,000 | +1.7% | 226,831 | +6.2% | 0.01% | 0.0% |
| Q3 2015 | $2,997,000 | +1.1% | 213,632 | +22.4% | 0.01% | +25.0% |
| Q2 2015 | $2,964,000 | – | 174,571 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |